Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Inclusion criteria:

Must have signed consent for Amendment 5
Must have completed visit 62 of the core IRIS trial or be in follow-up
Must be on STI571 treatment
If on IFN treatment, must be willing to cross over to STI571 treatment

Exclusion criteria:

Patients who have discontinued from the study and are in follow-up
Patients who are on IFN treatment and do not want to cross over to STI571 treatment
Patients who have not consented to amendment 5
Patients who did not complete the amendment 5 protocol

Additional protocol-defined inclusion/exclusion criteria may apply